In this study, we aimed to determine whether an inhibitory phenotype can account for the mutual exclusivity of KRAS and EGFR mutations in LUAD and to characterize the specific cellular effects that result from co-expression of both mutant alleles in lung cancer cells. The gene discussed is EGFR; the disease is lung carcinoma.